Clinical Trial Results:
Daptomycin concentration in drainage fluid and blood samples of ICU patients
Summary
|
|
EudraCT number |
2015-000125-36 |
Trial protocol |
DE |
Global end of trial date |
31 Mar 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Jun 2021
|
First version publication date |
23 Jun 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Dapto
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03004066 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University hospital Tübingen
|
||
Sponsor organisation address |
Hoppe-Seyler-Str. 3, Tübingen, Germany, 72076
|
||
Public contact |
Intensive Care Unit 39, University Hospital Tübingen, +49 070712986724, helene.haeberle@med.uni-tuebingen.de
|
||
Scientific contact |
Intensive Care Unit 39, University Hospital Tübingen, +49 070712986724, helene.haeberle@med.uni-tuebingen.de
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
22 Sep 2020
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
31 Mar 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Mar 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Pharmakokinetics of Daptomycin in intensive care patients with wound drainage after surgery
|
||
Protection of trial subjects |
all subjects received normal postoperative intensive care. No additional measures were necessary
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
06 Jul 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 9
|
||
Worldwide total number of subjects |
9
|
||
EEA total number of subjects |
9
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
7
|
||
From 65 to 84 years |
2
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
- | ||||||
Pre-assignment
|
|||||||
Screening details |
Patients receiving LVAD implantation for terminal heart failure | ||||||
Period 1
|
|||||||
Period 1 title |
baseline (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
not blinded
|
||||||
Arms
|
|||||||
Arm title
|
Daptomycin | ||||||
Arm description |
All patients received Daptomycin after LVAD implantation according to our internal standards. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Daptomycin
|
||||||
Investigational medicinal product code |
J01XX09
|
||||||
Other name |
|||||||
Pharmaceutical forms |
Powder and solvent for solution for injection/infusion
|
||||||
Routes of administration |
Infusion
|
||||||
Dosage and administration details |
6mg/kg per day, intravenous infusion
|
||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Daptomycin
|
||
Reporting group description |
All patients received Daptomycin after LVAD implantation according to our internal standards. | ||
Subject analysis set title |
blood concentrations
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
all patients included into the trial
|
||
Subject analysis set title |
drain fluid concentrations
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
all patients included into the trial
|
|
|||||||||||||||||
End point title |
concentrations [1] | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
day 1 to 3
|
||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: this trial was designed as a pilot project to determine whether a trial including more subjects could be done and should be planned. only 9 subjects were included into the trial. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
3 days
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
CTCAE | ||
Dictionary version |
5
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: within the monitored time period no adverse events where reported. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
08 Feb 2018 |
trial timeline was changed from 01.07.2016-01.07.2018
to 01.07.2016-31.03.2019 (end of trial) |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
this small trial included patients with terminal heart disease in need of a LVAD implantation and receiving Daptomycin for 3 days, which is a very small collective to recruit from. |